Immunogenicity and protection conferred by an optimized purified inactivated Zika vaccine in mice.

Immunogenicity and protection conferred by an optimized purified inactivated Zika vaccine in mice. Vaccine. 2019 Apr 06;: Authors: Lecouturier V, Bernard MC, Berry C, Carayol S, Richier E, Boudet F, Heinrichs J Abstract After decades of inconsequential infections, and sporadic outbreaks in the Asia-Pacific region between 2007 and 2013, Zika virus caused a widespread epidemic in South America in 2015 that was complicated by severe congenital infections. After the WHO declared a Public Health Emergency of International Concern in February 2016, vaccine development efforts based on different platforms were initiated. Several candidates have since been evaluated in clinical phase I studies. Of these, a Zika purified inactivated vaccine (ZPIV), adjuvanted with aluminum hydroxide, developed by the Walter Reed Army Institute of Research (WRAIR), yielded high seroconversion rates. Sanofi Pasteur further optimized the vaccine in terms of production scale, purification conditions and regulatory compliance, using its experience in flavivirus vaccine development. Here we report that the resulting optimized vaccine (ZIPV-SP) elicited robust seroneutralizing antibody responses and provided complete protection from homologous Zika virus strain challenge in immunocompetent BALB/c mice. ZIPV-SP also showed improved immunogenicity compared with the first-generation vaccine, and improved efficacy in the more permissive interferon receptor-deficient A12...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research